Versiani M, Mundim F D, Nardi A E, Liebowitz M R
Department of Psychiatry, Federal University of Rio de Janeiro, Brazil.
J Clin Psychopharmacol. 1988 Aug;8(4):279-83.
Thirty-two patients meeting DSM-III criteria for social phobia entered a 1-year drug treatment with tranylcypromine in dosages between 40 and 60 mg/day. After exclusion of the early dropouts, improvement was rated as marked and moderate in 62% and 17% of the sample (N = 29), respectively. Alcohol abuse was associated with a poor outcome. Side effects were frequent and in some cases delayed the attainment of efficacious dosages until the third month of treatment. No serious adverse reactions occurred. The findings, relative to efficacy, are in accordance with a previous trial with phenelzine but need confirmation in double blind controlled studies.
32名符合《精神疾病诊断与统计手册》第三版社交恐惧症标准的患者接受了为期1年的反苯环丙胺药物治疗，剂量为每日40至60毫克。排除早期退出者后，样本（N = 29）中分别有62%和17%的患者改善程度为显著和中等。酒精滥用与不良预后相关。副作用频繁出现，在某些情况下，直到治疗第三个月才达到有效剂量。未发生严重不良反应。关于疗效的研究结果与之前使用苯乙肼的试验一致，但需要在双盲对照研究中得到证实。
